Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Long-Term Investments (2016)

Celldex Therapeutics has reported Long-Term Investments over the past 1 years, most recently at $1.8 million for Q4 2016.

  • Quarterly results put Long-Term Investments at $1.8 million for Q4 2016, changed N/A from a year ago — trailing twelve months through Dec 2016 was $1.8 million (changed N/A YoY), and the annual figure for FY2016 was $1.8 million, changed.
  • Long-Term Investments for Q4 2016 was $1.8 million at Celldex Therapeutics.
  • Over the last five years, Long-Term Investments for CLDX hit a ceiling of $1.8 million in Q4 2016 and a floor of $1.8 million in Q4 2016.